DK2582683T3 - Behandling af gigt og hyperurikæmi - Google Patents

Behandling af gigt og hyperurikæmi Download PDF

Info

Publication number
DK2582683T3
DK2582683T3 DK11796324.9T DK11796324T DK2582683T3 DK 2582683 T3 DK2582683 T3 DK 2582683T3 DK 11796324 T DK11796324 T DK 11796324T DK 2582683 T3 DK2582683 T3 DK 2582683T3
Authority
DK
Denmark
Prior art keywords
gout
less
allopurinol
compound
instances
Prior art date
Application number
DK11796324.9T
Other languages
English (en)
Inventor
Jeffrey Miner
Barry D Quart
Jean-Luc Girardet
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348529&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2582683(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Application granted granted Critical
Publication of DK2582683T3 publication Critical patent/DK2582683T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (12)

1. Lesinurad eller et farmaceutisk acceptabelt salt deraf og allopurinol til anvendelse i profylakse eller behandling af allopurinol-refraktær gigt.
2. Lesinurad-natrium og allopurinol til anvendelse ifølge krav 1.
3. Lesinurad eller et farmaceutisk acceptabelt salt deraf og allopurinol til anvendelse ifølge krav 1, hvor gigten er kendetegnet ved tilstedeværelse af store akkumulerede aflejringer af urinsyre eller tophi.
4. Lesinurad eller et farmaceutisk acceptabelt salt og allopurinol til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor administration af lesinurad eller det farmaceutisk acceptable salt deraf til patienten er oral administration.
5. Lesinurad eller et farmaceutisk acceptabelt salt og allopurinol til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor administrationen af lesinurad eller det farmaceutisk acceptable salt deraf sker om morgenen.
6. Lesinurad eller et farmaceutisk acceptabelt salt deraf og allopurinol til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor den daglige dosis af lesinurad eller det farmaceutisk acceptable salt deraf er 200 mg.
7. Lesinurad eller et farmaceutisk acceptabelt salt deraf og allopurinol til anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor den daglige dosis af lesinurad eller det farmaceutisk acceptable salt deraf er 400 mg.
8. Lesinurad eller et farmaceutisk acceptabelt salt deraf og allopurinol til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor dosen af allopurinol er 100 mg til 300 mg.
9. Lesinurad eller et farmaceutisk acceptabelt salt deraf og allopurinol til anvendelse ifølge et hvilket som helst af kravene 2 til 7 til administration sammen med fødevare.
10. Allopurinol og farmaceutisk sammensætning, der omfatter lesinurad eller et farmaceutisk acceptabelt salt deraf, til anvendelse ifølge et hvilket som helst af kravene 1 til 9.
11. Allopurinol og farmaceutisk sammensætning, der omfatter lesinurad eller et farmaceutisk acceptabelt salt deraf, til anvendelse ifølge et hvilket som helst af kravene som 1 til 10, hvor dosen af allopurinol er 100 mg til 300 mg.
12. Lesinurad-natrium og allopurinol til anvendelse ifølge et hvilket som helst af kravene 2 til 8, hvor lesinuradnatriummet er amorft.
DK11796324.9T 2010-06-15 2011-06-14 Behandling af gigt og hyperurikæmi DK2582683T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35500410P 2010-06-15 2010-06-15
US41144910P 2010-11-08 2010-11-08
US201161430522P 2011-01-06 2011-01-06
US201161489420P 2011-05-24 2011-05-24
PCT/US2011/040398 WO2011159732A1 (en) 2010-06-15 2011-06-14 Treatment of gout and hyperuricemia

Publications (1)

Publication Number Publication Date
DK2582683T3 true DK2582683T3 (da) 2018-06-06

Family

ID=45348529

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11796324.9T DK2582683T3 (da) 2010-06-15 2011-06-14 Behandling af gigt og hyperurikæmi

Country Status (18)

Country Link
US (3) US9216179B2 (da)
EP (1) EP2582683B1 (da)
JP (1) JP5964821B2 (da)
CA (1) CA2802407C (da)
CY (1) CY1120473T1 (da)
DK (1) DK2582683T3 (da)
ES (1) ES2670700T3 (da)
HR (1) HRP20180780T1 (da)
HU (1) HUE038265T2 (da)
LT (1) LT2582683T (da)
NO (1) NO2019008I1 (da)
PL (1) PL2582683T3 (da)
PT (1) PT2582683T (da)
RS (1) RS57275B1 (da)
SI (1) SI2582683T1 (da)
TR (1) TR201806828T4 (da)
WO (1) WO2011159732A1 (da)
ZA (1) ZA201300055B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3659601A1 (en) 2010-03-30 2020-06-03 Ardea Biosciences, Inc. Treatment of gout
SI2582683T1 (en) * 2010-06-15 2018-07-31 Ardea Biosciences, Inc. Treatment of gout and hyperuricaemia
EA026101B1 (ru) * 2011-11-03 2017-03-31 Ардеа Биосайнсиз, Инк. Применение 3,4-дизамещенного пиридинового соединения для снижения уровня мочевой кислоты в сыворотке крови
AR091651A1 (es) 2012-07-03 2015-02-18 Ardea Biosciences Inc Elaboracion de acido 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetico
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
CN103613552A (zh) * 2013-12-02 2014-03-05 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸钠的新晶型及其制备方法
CN103755651A (zh) * 2013-12-23 2014-04-30 苏州晶云药物科技有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1，2，4-三唑-3-基硫基)乙酸的盐的新晶型及其制备方法
WO2015095703A1 (en) 2013-12-20 2015-06-25 Crystal Pharmatech, Inc. Novel salts and co-crystals of lesinurad
JP2015160847A (ja) * 2014-02-28 2015-09-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
WO2016203436A1 (en) * 2015-06-19 2016-12-22 Dr. Reddy's Laboratories Limited Amorphous and amorphous solid dispersion of lesinurad and their preparation
EP3112334A1 (en) 2015-06-29 2017-01-04 DPx Fine Chemicals Austria GmbH & CoKG Process for manufacturing 1-cyclopropyl-naphthalenes
JP6976946B2 (ja) * 2015-12-08 2021-12-08 アーディア・バイオサイエンシーズ・インコーポレイテッドArdea Biosciences, Inc. 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
CA3060185A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
CA3060193C (en) 2018-10-26 2023-05-09 The Procter & Gamble Company Paper towel rolls
CA3060180A1 (en) 2018-10-26 2020-04-26 The Procter & Gamble Company Sanitary tissue product rolls
US20220288038A1 (en) * 2019-08-21 2022-09-15 The University Of Tokyo Abcc11 inhibitor
CN110824067A (zh) * 2019-12-11 2020-02-21 天津药物研究院有限公司 一种非布司他中基因毒性杂质的检测方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063788A1 (ja) 2003-12-26 2005-07-14 Kissei Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体及びその医薬用途
US20060189811A1 (en) 2004-07-23 2006-08-24 Fujiyakuhin Co., Ltd. Process for producing 1,2,4-triazole compound and intermediate therefor
DK2135608T3 (da) 2004-08-25 2012-01-23 Ardea Biosciences Inc S-triazolyl-alfa-mercaptoacetanilider som inhibitorer for HIV-revers transkriptase
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
BRPI0806608A2 (pt) 2007-01-19 2011-09-06 Takeda Pharmaceuticals North America Inc métodos para prevenir ou reduzir o número de surtos agudos de gota utilizando inibidores xantina oxidoredutase e agentes anti-inflamatórios
NZ595035A (en) 2007-11-27 2012-11-30 Ardea Biosciences Inc Substituted diazole and triazole compounds and compositions and methods of use
US8173690B2 (en) * 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
US8242154B2 (en) * 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CA2735828C (en) 2008-09-04 2013-07-23 Esmir Gunic Substituted-(naphthalen-1-yl)-1h-imidazoles and their use for modulating uric acid levels
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
WO2010135530A2 (en) * 2009-05-20 2010-11-25 Ardea Biosciences, Inc. Compounds, compositions and methods for modulating uric acid levels
EP2266966A1 (en) 2009-06-11 2010-12-29 Chemo Ibérica, S.A. A process for the preparation of febuxostat
MY161482A (en) 2010-01-08 2017-04-14 Ardea Biosciences Inc Polymorphic, crystalline and mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnapthalen-1-yl)-4h-1,2,4-triazol-3-ylthio)acetate, and uses thereof
EP3659601A1 (en) 2010-03-30 2020-06-03 Ardea Biosciences, Inc. Treatment of gout
SI2582683T1 (en) * 2010-06-15 2018-07-31 Ardea Biosciences, Inc. Treatment of gout and hyperuricaemia
ES2706066T3 (es) * 2010-07-02 2019-03-27 Univ Health Network Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas
CA2813555C (en) * 2010-10-15 2014-11-25 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
EA022301B1 (ru) * 2010-12-30 2015-12-30 Ардеа Биосайнсиз, Инк. Полиморфные формы 2-(5-бром-4-(4-циклопропилнафталин-1-ил)-4h-1,2,4-триазол-3-илтио)уксусной кислоты и их применение
EA201370247A1 (ru) 2011-05-24 2014-07-30 Ардеа Биосайнсиз, Инк. Гипертония и гиперурикемия

Also Published As

Publication number Publication date
HUE038265T2 (hu) 2018-10-29
US20190015392A1 (en) 2019-01-17
WO2011159732A1 (en) 2011-12-22
ES2670700T3 (es) 2018-05-31
JP5964821B2 (ja) 2016-08-03
US9216179B2 (en) 2015-12-22
LT2582683T (lt) 2018-06-11
CA2802407C (en) 2018-01-23
RS57275B1 (sr) 2018-08-31
ZA201300055B (en) 2018-05-30
JP2013528650A (ja) 2013-07-11
CY1120473T1 (el) 2019-07-10
US20130178484A1 (en) 2013-07-11
HRP20180780T1 (hr) 2018-07-13
PT2582683T (pt) 2018-05-25
EP2582683B1 (en) 2018-03-21
EP2582683A1 (en) 2013-04-24
US20160143889A1 (en) 2016-05-26
NO2019008I1 (no) 2019-02-19
CA2802407A1 (en) 2011-12-22
EP2582683A4 (en) 2014-04-30
TR201806828T4 (tr) 2018-06-21
SI2582683T1 (en) 2018-07-31
PL2582683T3 (pl) 2018-08-31

Similar Documents

Publication Publication Date Title
US20190015392A1 (en) Treatment of Gout and Hyperuricemia
US9402827B2 (en) Treatment of gout
US20230414539A1 (en) Method of treating cardiovascular events using colchicine concurrently with an antiplatelet agent and statin
MX2015001732A (es) Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de p13k-alfa.
CA2914310A1 (en) Pharmaceutical combinations
JP2024001009A (ja) Ｐｉ３ｋ阻害剤であるｇｄｃ－００７７による癌の治療方法
US20070275989A1 (en) Therapeutic Treatment
WO2015022657A1 (en) Pharmaceutical combinations
US20230404971A1 (en) Combination Comprising Abemaciclib and 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid
US20240197739A1 (en) Combination Comprising Ribociclib and Amcenestrant
AU2008201290B2 (en) Therapeutic treatment
EP3265075B1 (en) Roneparstat combined therapy of multiple myeloma
AU2009272373A1 (en) Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
TW201315471A (zh) 使用ＰＩ３Ｋβ抑制劑及包括ＭＥＫ及ＲＡＦ抑制劑之ＭＡＰＫ通道抑制劑之供治療癌症之組合物及方法